New phase 3 analyses show that a single dose of REGEN-COV® (Casirivimab and Imdevimab) provides long-term protection against COVID-19
Single dose of REGEN-COV (1,200 mg subcutaneous) reduced the risk of COVID-19 by 81.6% during the pre-specified follow-up period (months 2-8), maintaining the 81.4% risk reduction previously reported during month 1.
Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose
The omicron variant of SARS-CoV-2 infected very large numbers of SARS-CoV-2 vaccinated and convalescent individuals 1–3.
Pfizer plans to submit data on a 4th Covid shot to FDA
Pfizer is close to submitting data to the Food and Drug Administration on a fourth dose of its Covid-19 vaccine, according to CEO Albert Bourla.
Omicron BA.2 sub-variant now nearly a quarter of new COVID cases in U.S., CDC estimates
The BA.2 sub-lineage of the Omicron variant now makes up nearly a quarter of new COVID-19 infections nationwide, the Centers for Disease Control and Prevention estimated Tuesday, up from around 1 in 10 new cases just a week prior.
Two cases of 'stealth omicron' COVID-19 variant detected in North Texas
UT Southwestern confirmed two cases of BA.2 in North Texas Thursday, a new mutation of the omicron variant of the coronavirus. Researchers identified these BA.2 cases through genomic sequencing. Medical experts have to analyze the genetic traits of BA.2 closely in order to diagnose it, which is why some refer to this new mutation as “stealth omicron.”